Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of ADI-PEG 20 in Relapsed or Refractory Small Cell Lung Cancer
2009-017885-22Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pegargiminase in small cell lung cancer (SCLC), sponsored by Ludwig Cancer Research. Primary endpoint: Tumor response (CR or PR). Started Apr 2012; status: completed.
02
Drugs
Pegargiminase
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2009-017885-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017885-22.